TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03093090

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parmalat™ Whole Milk
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parmalat™ Whole Milk
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parmalat™ Whole Milk
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parmalat™ Whole Milk
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Similac Pro-Advance™
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Similac Pro-Advance™
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Similac Pro-Advance™
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Similac Pro-Advance™
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus™
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus™
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus™
Description: 6 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus™
Description: 6 oz

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide 20 MG
Description: Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study: NCT04643457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: - Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: - Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
Study: NCT03093090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide 20 MG
Description: Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide 20 MG
Description: Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide 20 MG
Description: Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.
Study: NCT02694003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BNBD-NDD Intervention
Description: The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
Study: NCT02543450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular and task-oriented training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb strength training program
Study: NCT00963703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000 mg Intravenously day 1 and day 15
Study: NCT00972543

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Efalizumab (Raptiva)
Description: Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
Study: NCT01066156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel
Description: This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
Study: NCT02453230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lights on
Description: Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
Study: NCT03890120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: 100 mg tablet administered orally once daily
Study: NCT04493619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV injection, 5 mg•min/mL
Study: NCT03475394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gel
Description: 0.1 ml of Chlorhexidine gel was administered into the periodontal pocket

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morus alba gel
Description: 0.1 ml of Morus alba gel was administered into the periodontal pocket
Study: NCT04643457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: - Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous Placebo
Description: Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
Study: NCT03475394

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 ml of Placebo gel was administered into the periodontal pocket
Study: NCT03005535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitaminized corn oil
Description: Oil consumption at the two main meals, lunch and dinner (15gx2 per day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
Study: NCT00597558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egg white protein
Description: Egg white protein powder
Study: NCT03616769

Intervention type: DRUG
Intervention: antiplatelet drugs ,statins ,antihypertensive drugs
Description: According to the international guidelines, we treated patients who suffered from different disease.
Study: NCT02729454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice and physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Study: NCT01627756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Ventilation
Description: In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-ventilated Group
Description: . In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
Study: NCT03591705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE-HAIC
Description: transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC
Description: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
Study: NCT04303390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: second generation cephalosporin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: second generation cephalosporin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: First generation cephalosporin
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study: NCT04303390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: First generation cephalosporin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24 hours
Description: Duration of antibiotic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24 hours
Description: Duration of antibiotic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 48 hours
Description: Duration of antibiotic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 48 hours
Description: Duration of antibiotic therapy
Study: NCT04002453

Intervention type: PROCEDURE
Intervention: Outpatient Parenteral Antibiotic Therapy
Description: Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
Study: NCT04340830

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
Study: NCT01894516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules.
Study: NCT02975869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Leukemia Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care
Study: NCT03288974

Intervention type: DRUG
Intervention: POMALYST® (Pomalidomide)
Description: The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
Study: NCT04297657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling
Description: o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
Study: NCT01117051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 1 or 2 mg prucalopride once daily before breakfast
Study: NCT01415193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Tibial Nerve block
Description: Use of selective pain block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic Nerve Block
Description: Use of Sciatic Nerve Block
Study: NCT01087866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study: NCT02808572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma osteoprotegerin level
Description: dosage of plasma osteoprotegerin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma fibroblast growth factor 23 level
Description: dosage of plasma fibroblast growth factor 23
Study: NCT01544595

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab (AIN457)
Description: Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02808572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascular calcification score
Description: measurement of vascular calcification score by multidetection computerized tomography
Study: NCT00611039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir 900mg + ritonavir 100 mg once a day
Description: Darunavir 900mg + ritonavir 100 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir 600mg + ritonavir 100mg twice day
Description: Darunavir 600mg + ritonavir 100mg twice day
Study: NCT01464983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
Study: NCT03890120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: 100 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: 100 mg tablet administered orally once daily
Study: NCT03890120

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally once daily
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study: NCT04496167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Collagenase clostridium histolyticum
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study: NCT04052555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT03430973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videos
Description: Videos depicting various aggressive driving and road rage behaviors.
Study: NCT04496167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT02839135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated scopolamine patch
Description: Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed scopolamine patch
Description: Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
Study: NCT00156338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid management
Description: volume and sodium restriction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluid management
Description: volume restriction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluid management
Description: liberal fluid management
Study: NCT03430973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bumper stickers
Description: Bumper stickers hypothesized to increase or decrease aggressive driving.
Study: NCT01464983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
Study: NCT04643171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high intensity elliptical training
Description: 30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrocaupuncture
Description: 30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
Study: NCT05673564

Intervention type: PROCEDURE
Intervention: Anatomical Resection
Description: Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
Study: NCT03115580

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational atherectomy
Description: Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting Balloon Angioplasty
Description: Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
Study: NCT03155360

Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study

Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study
Study: NCT02069418

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FLT-TEP
Description: Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG-TEP
Description: Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
Study: NCT01337271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBT- PSV
Description: An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBT- PSV
Description: An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBT - NAVA
Description: An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
Study: NCT00896454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: 120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
Study: NCT03927872

Intervention type: OTHER
Intervention: blood biomarkers
Description: assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome

Intervention type: OTHER
Intervention: blood biomarkers
Description: assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome